Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 1Gastrointestinal 1

Conditions

Postoperative Stage II/III Colon Cancer 1Chemotherapy-induced Peripheral Neuropathy 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × ART123 × Clear all
NCT05251727 2024-08-19

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Veloxis Pharmaceuticals

Phase 1 Terminated
77 enrolled
Other

Chemotherapy-induced Peripheral Neuropathy

NCT02792842 2024-04-04

Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer

Asahi Kasei Therapeutics Corporation

Phase 2 Completed
79 enrolled 10 charts
Gastrointestinal

Postoperative Stage II/III Colon Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡